Expert Consultations: Real-World Answers

Pharmacotherapies for Stimulant Use Disorder – Interview

Published on December 1, 2022 Certification expiration date: December 1, 2028

Guest

Radwa Hanafy

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Mirtazapine may be effective for patients with methamphetamine use disorder. Patient education about its possible side effects is important in optimizing and maintaining adherence.
Stimulants, such as methylphenidate, are best prescribed to patients with stimulant use disorder and comorbid ADHD.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Andrew Saxon, M.D., who is an addiction psychiatrist and a professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine. In this interview, we will discuss pharmacotherapies for stimulant use disorders.

Radwa Hanafy, M.D.: I really enjoyed watching your lecture about pharmacotherapies for stimulant use disorders. I have to say that one thing that kept my mind wondering is the fact that we have

Unlock this Expert Consultation and earn 0.75 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Recognize the value of promoting behavioral interventions for patients with stimulant use disorders.
Determine strategies for the appropriate selection of psychotropic medications that may be used for the management of patients with stimulant use disorders.
Contrast the various psychotropic medications that may be used for the management of stimulant use disorders according to mechanisms of action, adverse effects, and dosing considerations.

Original Release Date: December 1, 2022

Review and Re-release Date: December 1, 2025

Expiration Date: December 1, 2028

Expert: Andrew Saxon, M.D.

Medical Editors: Radwa Hanafy, M.D., Melissa Mariano, M.D.

Relevant Financial Disclosures:

Andrew J.Saxon declares the following interests:

– Indivior, Inc.: Advisor

– UpToDate, Inc.: Royalties

All of the relevant financial relationships listed above have been mitigated by Medical Academy and the Psychopharmacology Institute.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Andrew Saxon, M.D.